Scarica l'app Stockscreener
1.80
5.26%
0.09
Precedente Chiudi:
$1.71
Aprire:
$1.73
Volume 24 ore:
1.72M
Relative Volume:
2.61
Capitalizzazione di mercato:
$207.49M
Reddito:
-
Utile/perdita netta:
$-26.33M
Rapporto P/E:
-6.3739
EPS:
-0.2824
Flusso di cassa netto:
$-17.65M
1 W Prestazione:
+26.76%
1M Prestazione:
+56.52%
6M Prestazione:
+73.08%
1 anno Prestazione:
+34.33%
Intervallo 1D:
$1.65
$1.82
Intervallo di 1 settimana:
$1.38
$1.82
Portata 52W:
$0.88
$1.82
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.80 | 175.21M | 0 | -26.33M | -17.65M | -0.2824 |
TAK
Takeda Pharmaceutical Co Adr
|
17.63 | 55.60B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.77 | 42.81B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.70 | 43.16B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.79 | 30.39B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
499.73 | 21.95B | 3.17B | 1.29B | 1.01B | 27.09 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-28 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-26 | Iniziato | ROTH MKM | Buy |
| 2024-04-22 | Iniziato | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Borsa (CRDL) Ultime notizie
Wall Street Zen Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to Hold - MarketBeat
MMCAP and MM Asset Management (CRDL) reveal 21.3M-share Cardiol Therapeutics stake - Stock Titan
Why Cardiol Therapeutics Inc Class A stock is sliding today - Wealth Awesome
Cardiol Therapeutics Inc Class A CRDL Earnings Beat Estimates by 50.0% - Wealth Awesome
Cardiol Therapeutics Inc. Stock Surges 5.66% as Trading Activity Spikes and Market Attention Builds - kalkine.ca
Cardiol Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results - TipRanks
Cardiol Therapeutics (NASDAQ:CRDL) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Cardiol Therapeutics (CRDL) posts Q2 2026 loss but extends cash runway to Q4 2027 - Stock Titan
Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
What’s Next For Cardiol Therapeutics (TSX:CRDL) Research? - Kalkine Media
Cardiol Therapeutics Advances CardiolRx in Pivotal Phase III Pericarditis Trial - MarketBeat
Will Cardiol Therapeutics Inc Class A (CRDL) Beat Estimates Again in Its Next Earnings Report? - Wealth Awesome
What's Going On With Cardiol Therapeutics Inc Class A Stock Tuesday? - Wealth Awesome
Cardiol Therapeutics at Canaccord Genuity: Phase III catalyst nears By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - tradingview.com
Cardiol Therapeutics (TSX:CRDL): The Oral Heart Drug Challenging Injectable Biologics Nears Its Big Test - kalkine.ca
CRDL Stock Price, Quote & Chart - ChartMill
Cardiol Therapeutics Inc (CRDL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cardiol Therapeutics (CRDL) Expected to Post Earnings on Thursday - MarketBeat
Stocks in play: Cardiol Therapeutics Inc. - The Globe and Mail
Cardiol Therapeutics to Present Heart Disease Pipeline at Canaccord Genuity Growth Conference - TipRanks
Cardiol Therapeutics Inc. (NASDAQ: CRDL) at Canaccord 46th Growth Conference - Stock Titan
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference - The Globe and Mail
Why Cardiol Therapeutics Inc Class A stock is rising today - Wealth Awesome
CRDL|Cardiol Therapeutics Inc|Price:1.300|Chg%:+0.030 - TradingKey
Cardiol Therapeutics Inc. (TSX:CRDL) Shares Decline as Biotech Risk, Clinical Uncertainty and Investor Caution Pressure Outlook - kalkine.ca
HC Wainwright Analysts Decrease Earnings Estimates for CRDL - MarketBeat
Cardiol Therapeutics Inc (CRDL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.180|Chg%:-0.050 - TradingKey
Cardiol Therapeutics Inc (CRDL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cardiol Therapeutics Inc (CRDL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRDL|Cardiol Therapeutics Inc|Price:1.330|Chg%:+0.020 - TradingKey
Cardiol Therapeutics Inc. Class A Revenue Breakdown – SWB:CT9 - TradingView
Cardiol Therapeutics (CRDL) Gains 4.13% as Bullish Momentum Builds Above $1.23 SupportDouble EMA - dars.gov.et
What's Going On With Cardiol Therapeutics Inc Class A Stock Monday? - Wealth Awesome
Why Cardiol Therapeutics Inc Class A stock is skyrocketing today - Wealth Awesome
Cardiol Therapeutics (TSX:CRDL) Expands Visibility Across Healthcare Sector - Kalkine Media
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data - t.co
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 - Investing.com
H.C. Wainwright reiterates Cardiol Therapeutics stock Buy rating at $9 By Investing.com - Investing.com Nigeria
Cardiol Therapeutics’ Phase II Pericarditis Data in JAHA Bolsters Near-Complete Phase III MAVERIC Trial - TipRanks
Cardiol Publishes Phase II MAVERIC Data in the Journal of the American Heart Association - the deep dive
Cardiol publishes phase II pericarditis study in medical journal By Investing.com - Investing.com South Africa
CRDL Reiterated by HC Wainwright & Co. -- Price Target Maintained at $9 - GuruFocus
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol publishes phase II pericarditis study in medical journal - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) publishes Phase II pericarditis data as Phase III nears full enrollment - Stock Titan
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association - PR Newswire
Cardiol Therapeutics Inc Azioni (CRDL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):